Ranbaxy Laboratories Ltd received approval from the US FDA to manufacture and market Doxycycline tablets 50mg, 75mg and 100mg in the US market. The office of Generic Drugs, FDA has determined the company formulations to be bioequivalent and have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co.

Annualized sale for Adoxa were $ 57.2 million of Doxycycline market which achieved sales of $ 62.70 million.

Doxycycline is indicated for a variety of infections when caused by susceptible strains or micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, and severe acne as adjunctive therapy.